Triadin 1 is a major transmembrane protein in cardiac junctional sarcoplasmic reticulum (SR), which forms a quaternary complex with the ryanodine receptor (Ca 2؉ release channel), junctin, and calsequestrin. To better understand the role of triadin 1 in excitation-contraction coupling in the heart, we generated transgenic mice with targeted overexpression of triadin 1 to mouse atrium and ventricle, employing the ␣-myosin heavy chain promoter to drive protein expression. The protein was overexpressed 5-fold in mouse ventricles, and overexpression was accompanied by cardiac hypertrophy. The levels of two other junctional SR proteins, the ryanodine receptor and junctin, were reduced by 55% and 73%, respectively, in association with triadin 1 overexpression, whereas the levels of calsequestrin, the Ca 2؉ -binding protein of junctional SR, and of phospholamban and SERCA2a, Ca 2؉ -handling proteins of the free SR, were unchanged. Cardiac myocytes from triadin 1-overexpressing mice exhibited depressed contractility; Ca 2؉ transients decayed at a slower rate, and cell shortening and relengthening were diminished. The extent of depression of cell shortening of triadin 1-overexpressing cardiomyocytes was rate-dependent, being more depressed under low stimulation frequencies (0.5 Hz), but reaching comparable levels at higher frequencies of stimulation (5 Hz). Spontaneously beating, isolated work-performing heart preparations overexpressing triadin 1 also relaxed at a slower rate than control hearts, and failed to adapt to increased afterload appropriately. The fast time inactivation constant, 1 , of the L-type Ca 2؉ channel was prolonged in transgenic cardiomyocytes. Our results provide evidence for the coordinated regulation of junctional SR protein expression in heart independent of free SR protein expression, and furthermore suggest an important role for triadin 1 in regulating the contractile properties of the heart during excitation-contraction coupling.
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The sarcoplasmic reticulum (SR) 1 plays a central role in the regulation of the cytosolic Ca 2ϩ concentration and for excitation-contraction coupling in cardiac muscle. Ca 2ϩ release from the junctional SR increases the cytosolic Ca 2ϩ concentration, which leads to initiation of the heartbeat by activation of the contractile mechanism. The SR-Ca 2ϩ ATPase (SERCA2a) in the free SR takes up Ca 2ϩ , thereby lowering the cytosolic Ca 2ϩ concentration and promoting muscle relaxation. Ca 2ϩ release in myocardium is controlled by a complex of proteins localized to the junctional SR. These proteins include (a) the Ca 2ϩ release channel or ryanodine receptor, which forms the foot structure on the cytoplasmic surface of the junctional SR membrane; (b) the 55-kDa high capacity Ca 2ϩ -binding protein calsequestrin, located in the lumen of the junctional SR; and (c) the junctional SR transmembrane proteins junctin and triadin, which have been proposed to anchor calsequestrin to the Ca 2ϩ release channel from the lumenal side of the junctional face membrane (1) (2) (3) .
Triadin was first detected as a 95-kDa integral membrane protein in junctional SR vesicles isolated from skeletal muscle (4, 5) . Subsequently, its primary structure was deduced from the cDNA sequence (6) . The single transmembrane domain of skeletal muscle triadin divides the protein into a short Nterminal cytoplasmic segment, and a highly charged C-terminal region, which accounts for the bulk of the molecule, situated in the lumen of the SR (6 -8) . Guo and Campbell (1) noticed an interaction of the lumenal domain of skeletal muscle triadin with the Ca 2ϩ release channel and calsequestrin, which occurred in a Ca 2ϩ -dependent manner. Others have suggested that a region of the cytoplasmic domain can also interact with the Ca 2ϩ release channel depending on the Ca 2ϩ concentration (9) .
In cardiac muscle, the primary isoform of triadin expressed is triadin 1 (10) , which accounts for greater than 95% of the total triadin present in the heart. Triadin 1 (cardiac triadin) is a shorter variant of skeletal muscle triadin, which appears to arise from alternative splicing of mRNA transcribed from a common triadin gene (2, 10) . On SDS-PAGE, cardiac triadin runs as a doublet of 35-and 40-kDa molecular mass proteins, corresponding to deglycosylated and glycosylated mobility forms of the protein, respectively (10) . Both cardiac and skeletal muscle triadin are identical for the first 257 amino acids, then cardiac triadin 1 ends abruptly, incorporating a short C-terminal tail of 21 amino acids that is unique (2, 10) . The regions common to cardiac and skeletal muscle triadin are the short cytoplasmic segments (residues 2-47), the transmem-* This work was supported by National Institutes of Health Grant HL-28556 (to L. R. J.), Deutsche Forschungsgemeinschaft Grant SFB 556 (to J. N.), and a postdoctoral fellowship from the Deutsche Gesellschaft fü r Kardiologie-Herz-und Kreislaufforschung (to U. K.). The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
§ To whom correspondence should be addressed: Inst. fü r Pharmakologie und Toxikologie, Westfä lische Wilhelms-Universitä t, Domagkstr. 12, 48149 Mü nster, Germany. Tel.: 49-251-8355510; Fax: 49-251-8355501; E-mail: kirchhef@uni-muenster.de. 1 The abbreviations used are: SR, sarcoplasmic reticulum; bp, base pair(s); MOPS, 3-(N-morpholino)propanesulfonic acid; PAGE, polyacrylamide gel electrophoresis; PCR, polymerase chain reaction; WT, wild-type; TRD, triadin; ANF, atrial natriuretic factor; I Ca , L-type Ca brane segments (residues 48 -68), and the highly charged lumenal domains (residues 69 -257). Notably, the highly charged lumenal domains, which are common to all triadins, are particularly enriched in repeating lysine and glutamic acid residues, organized into "KEKE motifs," which have been proposed to facilitate protein-protein interactions (11) (12) (13) . It is not surprising, then, that, like skeletal muscle triadin, the lumenal domain of cardiac triadin has also been shown to bind to both calsequestrin (2, 3, 14 -16) and the ryanodine receptor (2, 3) . Based on results of immunoprecipation and fusion-protein pulldown assays, a quarternary complex between triadin, junctin, calsequestrin, and the ryanodine receptor was proposed, which may be important for the orchestrated operation of Ca 2ϩ release in both cardiac and skeletal muscle (3) . Supporting this idea, the calsequestrin-binding domain of cardiac triadin was recently localized to a select run of only 25 amino acids (residues 200 -224), which incorporates a single KEKE motif (15) , suggesting that the protein-protein interactions occurring between triadin and other components of the SR junction are very specific and highly organized.
What is the precise function of cardiac triadin? This question has been difficult to address experimentally due to the relative inaccessibility of putative "structural" junctional SR proteins like triadin, junctin, and calsequestrin to both biochemical and electrophysiological study. An anchoring function for triadin (and junctin) seems obvious, due to the ability of triadin (and junctin) to bind to both the ryanodine receptor and calsequestrin when studied in vitro, in combination with the ultrastructural observation that calsequestrin appears to be adhered to the lumenal face of the ryanodine receptor when observed in intact muscle with use of electron microscopy (17) . Beyond simply anchoring calsequestrin to the ryanodine receptor, triadin may affect the channel activity of the ryanodine receptor directly. For example, application of skeletal muscle triadin to the purified ryanodine receptor incorporated in planar lipid bilayers inhibits the channel activity of the protein (18, 19) . As part of a program to better understand the function of junctional SR proteins in myocardium, we initiated a strategy in which key junctional SR proteins are overexpressed in transgenic mouse hearts. With use of this approach for overexpression of cardiac calsequestrin, we demonstrated a greater than 10-fold increase in caffeine-induced Ca 2ϩ release in transgenic cardiomyocytes (17) , providing the first physiological evidence implicating cardiac calsequestrin as the storage protein for the lumenal Ca 2ϩ that is released during muscle contraction, an idea that has long been hypothesized, but difficult to demonstrate experimentally. Using the same transgenic mouse model, we observed that with overexpression of cardiac calsequestrin, the associated junctional SR proteins triadin, junctin, and the ryanodine receptor were down-regulated, whereas the free SR proteins SERCA2a and phospholamban were up-regulated (17) , showing for the first time that protein expression at the junctional SR of the heart can be regulated independently from protein expression at the free SR.
Here, we describe physiological experiments with transgenic mice overexpressing canine triadin 1 in myocardium (10) . Similar to results obtained with forced overexpression of calsequestrin (17), we observed that, with forced overexpression of triadin 1, selective down-regulation of other proteins of the junctional SR can occur, independently from changes in expression levels of proteins of the free SR. In addition, the contractile phenotype of hearts from triadin 1-overexpressing mice is altered. Hearts from triadin 1-overexpressing mice exhibit hypertrophy, impaired relaxation, blunted contractility with increased pressure loading, and frequency-dependent changes in myocyte shortening. Our results suggest that triadin 1 plays an active role in Ca 2ϩ release in the heart, beyond its previously proposed structural role of anchoring of calsequestrin to the ryanodine receptor.
EXPERIMENTAL PROCEDURES
Experimental Animals-Generation of the transgenic mouse lineage overexpressing canine triadin 1 was performed as described recently (10) . Screening for transgene-positive mice was done by polymerase chain reaction (20, 21) . All experiments described here were performed on female mice 16 -18 weeks of age. Animals were handled and maintained according to approved protocols of the animal welfare committees of the University of Mü nster (Mü nster, Germany) and Indiana University (Indianapolis, IN) .
Morphological Studies-For macroscopic and histological examination of mouse hearts, single longitudinal cuts were made along the length of the myocardium. Hearts were then weighed and immediately fixed in 4% buffered formalin, dehydrated, and embedded in paraffin. Longitudinal tissue sections of 5 m thickness were obtained from the right and left ventricular free wall, and sections were stained with hematoxylin-eosin, and periodic acid-Schiff reagent. Myocyte size was quantified morphometrically with a computer-assisted image analysis system (KS 300, Zeiss, Germany). The image analyzer was interfaced to a video camera connected to a Zeiss microscope. Finally, each field was transformed into a digital binary image. The mean cardiomyocyte diameter was calculated by measuring 100 cells/heart in the region of the cell nucleus using the two-point distance function of the analysis system. For electron microscopy, small pieces of left ventricular heart tissue were fixed by immersion with 2.5% glutaraldehyde in 0.1 M phosphate buffer. After fixation, the specimens were further fixed in buffered 1% osmium tetraoxide for 2 h, dehydrated in graded ethanol series, and embedded in Epon. Ultrathin sections were cut and stained with uranyl acetate and lead citrate. The sections were investigated under a Philips CM 10 transmission electron microscope.
Measurement of Blood Pressure and Heart Rate-The systolic, mean, and diastolic blood pressures were measured in unanesthetized mice with the tail-cuff method (22) and recorded on a monitor. Heart rate was computed from the amplitude of the pulse signal. The mice were held in the chamber for 10 min before the measurements were started. 25 single measurements made over a period of 5 days were averaged for each mouse.
Northern Blot Analysis-Total RNA from single mouse ventricles was isolated as described by Chomczynski and Sacchi (23) . 20 g of total cardiac RNA was separated by electrophoresis, transferred to nylon membranes, and hybridized with dog triadin and mouse atrial natriuretic factor (ANF) cDNA probes. For the generation of radioactively labeled cDNA probes by reverse transcriptase-PCR standard protocols were employed, using the cDNA as template in the presence of ␣-32 Plabeled nucleotides. Primers used had the following sequences: 5Ј-GATATCGAATTCACCATGACTGAGA (forward, dog triadin 1) and 3Ј-TCACTGTATCTGCTTCTTGCCC (reverse, dog triadin 1), and 5Ј-CGTGCCCCGACCCACGCCAGCATGGGCTCC (forward, mouse ANF) and 3Ј-GGCTCCGAGGGCCAGCGAGCAGAGCCCTCA (reverse, mouse ANF). PCR products of expected sizes were obtained for triadin 1 (852 bp) and for ANF (393 bp). The identity of PCR products was confirmed by cycle sequencing using an ABI-PRISM-310 automated sequencer (Applied Biosystems, Weiterstadt, Germany).
Preparation of Homogenates and Microsomal Membranes-For analysis of crude homogenates from individual hearts, single hearts from wild-type or triadin 1-overexpressing mice were homogenized at 4°C for 1 min in 1.2 ml of medium containing 20 mM MOPS (pH 7.0) and 0.25 M sucrose, using an Omni homogenizer (Omni International). The concentration of calcium in the homogenates was determined using Arsenazo III calcium reagent as recommended by the manufacturer (Sigma). Homogenate protein was stored frozen at Ϫ40°C. For preparation of cardiac microsomes partially enriched in sarcoplasmic reticulum, 11 control ventricles or 11 transgenic ventricles were pooled and homogenized at 4°C for 90 s in 25 ml of medium containing 0.25 M sucrose, 30 mM histidine (pH 7.4), using a Polytron PT-10 homogenizer (Kinematica, Lucerne, Switzerland) at a setting of 20,000 rpm. Control and transgenic homogenates were centrifuged at 1,500 ϫ g max for 10 min at 4°C, and the supernatants were collected and centrifuged at 45,000 ϫ g max for 30 min. The pellets from the second spin were resuspended in 20 ml of 0.6 M KCl, 30 mM histidine (pH 7.0) and recentrifuged at 64,000 ϫ g max for 30 min. The KCl-extracted microsomes were resuspended in 0.25 M sucrose, 10 mM histidine (pH 7.0) and stored frozen in small aliquots at Ϫ40°C.
SDS-PAGE, Immunoblotting, and Antibodies-Homogenates or mi-crosomal samples were solubilized at room temperature in 5% SDS buffer containing 62.5 mM Tris/HCl (pH 6.8), 5% glycerol, 40 mM dithiothreitol, and a trace of bromphenol blue. For immunoblot analysis of all proteins other than the ryanodine receptor, 16 -50 g of homogenate or membrane protein were separated on 8% SDS-PAGE according to the method of Porzio and Pearson (24) . For immunoblotting of ryanodine receptors from homogenate samples, 200 g of protein were applied per gel lane and electrophoresis was in 5% polyacrylamide. After transferring of proteins to nitrocellulose, the blots were incubated with different antibodies. The amount of bound protein was detected by 125 I-labeled protein A and quantified using a PhosphorImager (Bio-Rad). The following antibodies were used for detection of SR proteins: for the ryanodine receptor, mouse monoclonal antibody 1E9 (3) was used; for SERCA2a, mouse monoclonal antibody 2A7-A1 was used (16); for calsequestrin, affinity-purified rabbit antibody raised to canine cardiac calsequestrin was used (25) ; for junctin, affinity-purified rabbit antibody raised to the C-terminal 15 amino acids of mouse junctin was used; and for phospholamban, mouse monoclonal antibody 2D12 was used (26) . Two different antibodies were used for detection of triadin. Mouse monoclonal antibody 8G5 was raised to recombinant canine triadin 1 expressed and purified from Sf21 insect cells (10) . This antibody did not cross-react with mouse triadin 1. The TRN6 antibody was raised in a rabbit to a peptide corresponding to residues 146 -160 of mouse triadin and affinity-purified (10). This antibody cross-reacted with canine triadin but may not recognize canine triadin as strongly as mouse triadin, because within the peptide used to produce the antibody (residues 146 -160 of mouse triadin), there are three amino acid differences between mouse and dog triadin. Protein concentrations were determined according to the method of Lowry et al. (27) . 3 H]ryanodine. Nonspecific binding was determined in the same buffer containing in addition 10 M cold ryanodine. Samples were filtered, rinsed repetitively with ice-cold saline, and the remaining radioactivity on the filters was quantified in a liquid scintillation counter (16) . Ca 2ϩ -ATPase Assay-Ca 2ϩ -ATPase activity of microsomal membranes was measured at 37°C in buffer containing 50 mM MOPS (pH 7.2), 3 mM MgCl 2 , 100 mM KCl, 5 mM NaN 3 , 3 g/ml A23187, 1 mM EGTA, and 0 -1.0 mM added CaCl 2 to give the desired ionized Ca 2ϩ concentrations (28) . P i release from ATP was measured colorimetrically, and Ca 2ϩ -dependent activities were analyzed. Isolation of Cardiomyocytes-Ventricular myocytes were isolated from control and triadin 1-overexpressing mouse hearts using a published protocol (29) . Animals were pretreated with heparin (5 units/g body weight), and later anesthetized with CO 2 . Mouse hearts were excised, and the cannulated aorta was fixed to a Langendorff apparatus. Hearts were perfused for 5 min at 2 ml/min with a Ca 2ϩ -free solution (solution A) composed of (in mM) 140 NaCl, 5.8 KCl, 0.5 KH 2 PO 4 , 0.4 NaH 2 PO 4 , 0.9 MgSO 4 , 10 HEPES, 11.1 glucose (pH 7.1), followed by a perfusion for 30 min with solution A supplemented with 0.2 mg/ml collagenase (type D, Roche Molecular Biochemicals). Ca 2ϩ concentration was gradually increased during digestion to 100 M. After enzymatic digestion, the hearts were perfused for 10 min with solution A. The ventricles were cut into several pieces and subjected to gentle agitation through a nylon mesh to separate the myocytes.
Measurement of Ca 2ϩ Transient [Ca] i -Cardiomyocytes were incubated for 5 min at room temperature with solution A containing in addition 2.5 mM CaCl 2 , 50 mg/l ascorbic acid (solution B), and 25 M Indo-1/AM. The cells were then superfused with solution B without dye for 45 min before the measurements started. Indo-1 fluorescence was recorded at room temperature from single myocytes using a dual-emission microfluorescence system (Photon Technologies Inc., South Brunswick, NJ). Excitation was at 365 nm, and the emitted fluorescence was recorded at 405 and 495 nm. The ratio of fluorescence at the two wavelengths was used as an index of cytosolic Ca 2ϩ concentration. Cardiomyocytes were stimulated at 0.5 Hz with platinum electrodes placed on the sides of the experimental chamber. Data were collected at 20 Hz, and acquisition and processing were supported by Felix 1.1 software (Photon Technologies Inc., South Brunswick, NJ).
Cardiomyocyte Shortening Measurements-Contractility of isolated cardiomyocytes was recorded with a Panasonic video recorder AG-7350 (Matsushita Electric Ind. Co., Japan). Cardiomyocyte shortening was visualized on a monitor (Pieper WV-5410, Pieper AG, Mellingen, Switzerland), and connected to a video integrator (Pieper Video Integrator 310A) interfaced to a video camera (Pieper Kamera FK7512-IQ). The video camera was attached to a Leica microscope (Wetzlar, Germany).
Edge detection measurements were performed at room temperature on intact, rod-shaped cells, which had no spontaneous contractions or microblebs. Cells were placed in a chamber (1 ml) and perfused at 0.5-1 ml/min with solution A containing 1 mM CaCl 2 . Cardiomyocytes were electrically stimulated at the indicated frequencies. The maximal magnitude of contraction was normalized to resting cell length and expressed as percentage of shortening.
Whole 
Measurement of Cardiac Contractile Parameters in Work-performing Heart
Preparations-Work-performing heart preparations were utilized as described previously (31) . Mice were anesthetized intraperitoneally with 2.0 g/kg body weight urethane and treated with 1.5 units of heparin. Hearts were removed from the opened chest, immediately attached by the aorta to a 20-gauge cannula, and perfused retrogradely with oxygenized Krebs-Henseleit buffer (37.4°C) containing (mM) NaCl 118, NaHCO 3 25, Na-EDTA 0.5, KCl 4.7, KH 2 PO 4 1.2, MgSO 4 1.2, CaCl 2 2.5, and glucose 11. During the short period of retrograde perfusion, the pulmonary vein was cannulated. The perfusion of the heart was then changed to an anterograde mode. The venous return (preload) and the aortic pressure (afterload) were adjusted to 5 ml/min cardiac output and 50 mmHg, respectively. Loading conditions were changed then by increasing the aortic pressure (afterload) to 60 mmHg, while keeping the venous return constant. Heart rate, aortic pressure, left intraventricular pressure (systolic, diastolic, and end diastolic), and atrial pressure were measured and monitored continuously. The first derivative of left intraventricular pressure (ϩdP/dt and ϪdP/dt), time to peak pressure/mmHg, and time to half-relaxation/mmHg were calculated with a computer program (BeMon 2.1, Ingenieurbü ro Jä ckel, Hanau, Germany). Cardiac output and coronary flow were calculated from the parameters above. Statistical Analysis-Data are reported as means Ϯ S.E. Statistical differences between the different types of mice were calculated by analysis of variance followed by Bonferroni's t test. p Ͻ 0.05 was considered significant.
RESULTS
Triadin 1-overexpressing Mice-We used the ␣-myosin heavy chain promoter to drive cardiac-specific overexpression of canine triadin 1 in mouse hearts (32) . Northern blot analysis using a probe specific for canine triadin 1 revealed abundant mRNA production by the transgene (Fig. 1A) . Selective overexpression of canine triadin 1 in transgenic mouse hearts was demonstrated by immunoblotting cardiac microsomes with the triadin monoclonal antibody 8G5-G3, which detects only the canine isoform of the protein (Fig. 1B) . The two prominent mobility forms of triadin 1 (T1) detected, of molecular masses 35 and 40 kDa, were reported previously and correspond to deglycosylated and glycosylated () forms of the protein, respectively (10) . When the same membrane samples were probed with the TRN6 antibody, which recognizes both mouse and dog triadin 1, the substantial overexpression of triadin 1 in transgenic membranes was evident (Fig. 1C) . The level of the triadin 1 (T1) signal was increased by 5-fold (Table II) in microsomes from triadin 1-overexpressing mice compared with microsomes from wild-type mice, when using the TRN6 anti-body to estimate protein overexpression. The TRN6 antibody may underestimate overexpression of canine triadin 1 somewhat, however, because this antibody was raised to amino acid residues 146 -160 of mouse triadin, which are only 80% conserved in dog triadin. Overexpressed triadin 1 was easily visible on SDS-PAGE and Coomassie Blue staining of cardiac microsomes from transgenic mice, but endogenous triadin 1 could not be visualized with certainty when using microsomes from control mice (data not shown).
Cardiac Hypertrophy-Triadin 1-overexpressing hearts from adult mice (16 -18 weeks of age) exhibited a mild degree of hypertrophy, as indicated by an increase in heart mass and heart to body weight ratio relative to hearts from wild-type mice ( Fig. 2A, Table I ). We observed an enhanced heart weight and heart to body weight ratio already in 10-week-old triadin 1-overexpressing mice. However, all triadin 1-overexpressing mice studied (10 -18 months of age) had a normal mortality compared with control mice. Moreover, in contrast to results recently obtained with calsequestrin-overexpressing mice (17, 33) , triadin 1-overexpressing mice showed no overt signs of heart failure (e.g. no ascites or pulmonary congestion). Interestingly, triadin 1-overexpressing hearts were covered with white fibrotic plaques of varying size and shape ( Fig. 2A) . We believe these plaques contained large amounts of Ca 2ϩ , because the cardiac homogenates from triadin 1-overexpressing mice contained substantially more Ca 2ϩ than did the homogenates from control mice (2.84 Ϯ 0.66 mM [Ca 2ϩ ] versus 0.61 Ϯ 0.07 mM [Ca 2ϩ ], in homogenates from triadin 1-overexpressing and control mouse hearts, respectively; n ϭ 7; p Ͻ 0.05). Ca 2ϩ carry-over from triadin 1-overexpressing heart homogenates was sufficient to interfere significantly with Ca 2ϩ response assays on [ 3 H]ryanodine binding and Ca 2ϩ -ATPase activities of crude homogenates. However, we observed that the material containing the contaminating Ca 2ϩ could be removed by low speed centrifugation at 1,500 ϫ g max . Consequently, the Ca 2ϩ response experiments were conducted with cardiac microsomes, which were free from the interfering Ca 2ϩ . Longitudinal sections showed an increase of wall thickness in both ventricular chambers from triadin 1-overexpressing mice, and histological examination revealed that triadin 1-overexpressing cardiomyocytes from right and left ventricles were bigger than control cardiomyocytes (Table I) . Electron microscope analysis (using 16 -18-week-old mice) revealed that myofibrillar structure was disrupted with partial separations occurring in single fibers (Fig. 2B) . In addition, the myofibrils were frequently displaced by an undefined electron-dense matrix and the mitochondria were disorganized. The myofibrillar abnormalities noted along with the mitochondrial disorganization are indicators of a diseased heart in early stages of failure, although no overt failure was noted in the animals. In sharp contrast to calsequestrin-overexpressing mice (17), the microarchitecture of the junctions between the SR and the surface membrane or between the SR and T-tubules was not obviously disturbed. Hypertrophy was also accompanied by a 4-fold higher ANF mRNA expression in triadin 1-overexpressing mouse hearts. Mean blood pressure and heart rate were comparable between triadin 1-overexpressing mice and wild-type mice (data not shown).
Expression Levels of Other SR Proteins-To see if overexpression of triadin 1 in transgenic mouse hearts altered the expression levels of other SR proteins, we immunoblotted crude cardiac homogenates from control and triadin 1-overexpressing mice, using an array of antibodies raised to different SR proteins. Proteins arising from free or junctional SR membranes were analyzed (Fig. 3, Table II ). Expression levels of SERCA2a and phospholamban, proteins originating from free SR (16, 28) , were unaltered in triadin 1-overexpressing homogenates. Likewise, the expression level of calsequestrin, the intralumenal Ca 2ϩ -binding protein localized to junctional SR (17, 28) , was unchanged. In contrast, the expression levels of the two other junctional SR proteins analyzed, the ryanodine receptor and junctin (17, 28) , were decreased by 55% and 73%, respectively, when assessed by immunoblotting. The structural and sequence similarities between triadin and junctin were noted previously (10, 16) , and it is interesting that junctin was the SR protein most down-regulated in heart, when triadin 1 was overexpressed. The down-regulation of the ryanodine receptor in triadin 1- (Table III) ; however, the rate of decay of the Ca 2ϩ transient was markedly decreased in triadin 1-overexpressing cardiomyocytes. The time to 50% decay of the Ca 2ϩ transient was increased by 74%. To determine how the altered [Ca] i kinetics influenced contractility, we measured cardiomyocyte shortening using an edge detection system. Maximal cell shortening was depressed by 72% in triadin 1-overexpressing cardiomyocytes (Table III) , and, consistent with Ca 2ϩ transient observations, the kinetics of shortening were prolonged, with transgenic myocytes taking a 23% longer time to relax than control myocytes (Table III) .
Cardiomyocyte Shortening-frequency Relationship-A correlation between an impaired SR-Ca 2ϩ handling and an altered force-frequency relationship in myocardium has been described previously (35, 36) . Therefore, we compared the shorteningfrequency relationship in isolated cardiomyocytes from wildtype and triadin 1-overexpressing mice. Remarkably, the contractile abnormalities noted above observed at low stimulation frequencies between 0.5 to 3 Hz disappeared when the stimulation frequency was increased to 4 -5 Hz (Fig. 4) . These results demonstrate that the depressant effect of triadin 1 overexpression on myocardial contractility is rate-dependent, with the major effects occurring at very low stimulation frequencies which are not typically encountered in normally beating mouse hearts.
Contractile Parameters in Work-performing Heart Preparations-To see if contractile abnormalities in triadin 1-overexpressing cardiomyocytes persisted to the whole heart level, isolated hearts from wild-type and triadin 1-overexpressing mice were perfused in the work-performing mode. Under basal loading conditions utilized (50 mmHg aortic pressure), triadin 1-overexpressing mice and wild-type mice exhibited similar spontaneous heart rates and similar levels of systolic intraventricular pressure (Table IV) . However, the maximal rate of relaxation (ϪdP/dt) was decreased by 18% in triadin 1-overexpressing hearts, and relaxation times were prolonged (Table  IV) . Triadin 1-overexpressing hearts responded to increased afterload with blunted contractility. The rates of contraction (ϩdP/dt) and rates of relaxation (ϪdP/dt) were decreased at 60 mmHg by 15% and 20%, respectively (Table IV) . Furthermore, the systolic and diastolic intraventricular pressures were lower in triadin 1-overexpressing hearts (Table IV) .
Characteristics of L-type Ca 2ϩ Channel-To test whether the altered Ca 2ϩ handling in triadin 1-overexpressing cardiomyocytes was accompanied by changes in the trigger for SR-Ca 2ϩ release, we measured the L-type Ca 2ϩ channel current (I Ca ) in control and triadin 1-overexpressing cardiomyocytes. Cell membrane capacitance was increased in triadin 1-overexpress- 3 . SR protein levels in homogenates from transgenic hearts. Control (C) and triadin 1-overexpressing (T) heart homogenates were subjected to immunoblot analyses. Identical amounts of protein were loaded per lane for each antibody utilized. Blots were probed with antibodies specific for ryanodine receptor (RyR), Ca 2ϩ pump (SERCA2a), calsequestrin (CSQ), triadin 1 (TRD), junctin (JCN), and phospholamban (PLB) as described under "Experimental Procedures".
ing cardiomyocytes compared with wild-type myocytes (241.4 Ϯ 9.3 pA versus 196.5 Ϯ 7.9 pA, respectively; n ϭ 10 -14; p Ͻ 0.05), consistent with greater size of the transgenic cardiomyocytes observed in the histological examination. The kinetics of inactivation of the L-type Ca 2ϩ channel was impaired in triadin 1-overexpressing cells. The fast time constant of inactivation of I Ca , 1 , was increased by 20% in triadin 1-overexpressing cardiomyocytes (6.5 Ϯ 0.4 ms in transgenic versus 5.4 Ϯ 0.2 ms in control, n ϭ 10 -14, p Ͻ 0.05), whereas the slow time constant of inactivation of I Ca , 2 , was not significantly altered (41.6 Ϯ 1.8 ms in transgenic versus 46.5 Ϯ 2.8 ms in control, n ϭ 10 -14). At depolarizing potentials between ϩ20 to ϩ30 mV, the normalized I Ca current densities were reduced in triadin 1-overexpressing cardiomyocytes (Fig. 5) .
DISCUSSION
Cardiac triadin is localized in the junctional SR, where it appears to "anchor" calsequestrin to the Ca 2ϩ release channel. The functional consequences of this interaction in the heart have not previously been investigated. Here, we used a transgenic model of triadin 1 overexpression in the heart to show that overexpression of triadin 1 produces selective down-regulation of other junctional SR proteins, cardiac hypertrophy, and contractile abnormalities, with the most notable effect being on cardiac relaxation parameters. In addition, our study suggests that the triadin 1 protein level is an important determinant of the force-frequency relationship in myocardium.
What is the reason for the hypertrophy observed in triadin 1-overexpressing mice? Compared with the hypertrophy observed with overexpression of the associated junctional SR protein, calsequestrin, which gives striking cardiomegaly (2-fold increase in heart weight) and progresses rapidly to heart failure and early death (17) , the hypertrophy associated with triadin 1 overexpression is relatively benign (16% increase in heart to body weight ratio at 16 -18 weeks). It does not appear to yield a phenotype of overt heart failure or early death. Nonetheless, key indicators of hypertrophy and failure, like elevated ANF and increased myocyte size and increased cell capacitance, are evident in triadin 1-overexpressing mice. Cardiac hypertrophy is a fundamental adaptation of the adult heart to mechanical stress and humoral factors but can also occur from primary alterations in cardiac gene expression (37) . The final cause is an increased protein synthesis, possibly combined with a prolonged half-life of cardiac structural proteins. Postnatal cardiomyocytes are not capable of cell division, but they can adapt to load by an increase of cardiomyocyte size, changes in the rate of protein synthesis, and reactivation of a fetal gene regulatory program (38 -40) . In recent studies, it has been shown that an increased diastolic intracellular Ca 2ϩ level can act as a hypertrophic signal (41) (42) (43) Fig. 3 (n ϭ 7) we observed a significant increase in plaque-like material on the surfaces of triadin 1-overexpressing mouse hearts, which appeared to be composed partially of Ca 2ϩ concretions. The total Ca 2ϩ content of triadin 1-overexpressing heart homogenates was substantially increased, but the origin of "extra" Ca 2ϩ remains undefined at present. Recent findings by Carrion and co-workers (44) demonstrated that even slight elevations of Ca 2ϩ can stimulate the DNA-binding transcriptional regulator protein DREAM, thus inducing the expression of several growth genes. This pathway was considered in a transgenic mouse model with targeted overexpression of the ␣ 1 subunit of the L-type Ca 2ϩ channel, which exhibited a mild cardiac hypertrophy (45) . At present, however, we can only speculate which Ca 2ϩ -activated pathway may lead to the hypertrophy observed in the present model. Interestingly, transgenic hearts adapted to overexpression of triadin 1 by down-regulating the levels of two other junctional proteins involved in Ca 2ϩ release function, the Ca 2ϩ release channel and junctin. The level of the other junctional SR protein, calsequestrin, remained unchanged, as did the levels of the two free SR proteins, the Ca 2ϩ pump and its associated regulatory protein phospholamban. It may be that, in attempting to hold the amount of Ca 2ϩ release from the junctional SR as close to normal as possible when triadin 1 is overexpressed, the SR adapts by down-regulating other junctional proteins, including the ryanodine receptor and junctin. Calsequestrin may remain unchanged acting as a "set point" or "barometer" for maintaining intralumenal Ca 2ϩ constant, whereas the other junctional SR proteins may adapt around this set point to maintain the net Ca 2ϩ release as close to normal as possible. The protein most down-regulated with triadin 1 overexpression, junctin, is the protein most homologous to triadin, providing additional evidence that the two proteins have similar functions, i.e. anchoring calsequestrin to the ryanodine receptor and modulating Ca 2ϩ release (3, 15) . Interestingly, immunoblot analysis indicated that the protein level of the ryanodine receptor was down-regulated 55% in triadin 1-overexpressing mouse hearts, whereas the [ 3 H]ryanodine binding assay suggested that the ryanodine receptor was down-regulated only 30%. Since ryanodine only binds to open Ca 2ϩ release channels, it could be that in triadin 1-overexpressing hearts, compensatory biochemical changes are occurring allowing the ryanodine receptor to become more easily activable, thus partially offsetting the substantial decrease in the total level of receptors that are present. However, the ryanodine receptor in triadin 1-overexpressing mouse heart microsomes was no more responsive to Ca 2ϩ than was the ryanodine receptor in control heart microsomes. It is possible that other regulatory factors are involved.
The major physiological effects of triadin 1 overexpression on Ca 2ϩ transients and contractility of cardiac myocytes occurred at low stimulation frequencies and were predominately on relaxation indices. For example, decay of the Ca 2ϩ transient, rate of cell shortening, and rate of whole heart relaxation (at basal loading conditions) were substantially prolonged in triadin 1-overexpressing myocytes. The maximal extent of cell shortening was also substantially reduced, however. These observations suggest that, at low stimulation frequencies, the net reuptake rate of Ca 2ϩ by the SR, as well as the net release of Ca 2ϩ , may be substantially impaired. The biochemical cause (or causes) for these physiological changes are difficult to ascribe directly to over-or underexpression of a single protein, because so many proteins are changing concurrently. We can conclude that triadin 1 overexpression in the heart has significant physiological effects on cardiac contractility, which includes aberrations in both net Ca 2ϩ uptake and Ca 2ϩ release by the SR. Other effects, such as prolongation of I Ca current kinetics, are probably secondary to impaired Ca 2ϩ release from channel. The impaired contractility detected occurred mostly at low stimulation frequencies in triadin 1-overexpressing mice, whereas at higher stimulation frequencies, which are closer to normal for the mouse, the contractile responses were similar. These frequency-dependent contractile changes may imply that the altered junctional SR protein levels, including profound down-regulation of junctin, are adaptive responses occurring to maintain SR Ca 2ϩ release/homeostasis as close to normal as possible at the normal mouse heart rate. It is conceivable that at lower heart rates the protein adaptations are no longer appropriate and contractility regulation breaks down. As a result, the SR can no longer regulate Ca 2ϩ with fidelity, and contractile changes become obvious (Fig. 4) .
In summary, we have shown that triadin 1 plays an important role in the force-frequency relationship. It may be that adult triadin 1-overexpressing mice escape overt heart failure because other junctional SR proteins down-regulate to allow Ca 2ϩ release to remain close to normal at the normal mouse heart rate. To test this hypothesis, we are currently mating junctin-overexpressing mice (46) with triadin 1-overexpressing mice so that forced overexpression of both proteins can occur simultaneously.
